Artivion Inc. (AORT) PT Raised to $40 at Canaccord

Canaccord analyst William Plovanic raised the price target on Artivion Inc. (NYSE: AORT) to $40.00 (from $39.00) while maintaining a Buy rating.

The analyst comments "This note serves as a model update for our Artivion estimates. We are adjusting our revenue estimates to reflect the additional data contained in the company’s 10-Q filing for Q2. Our price target is raised to $40 from $39 due to a change in the comp group multiple, as our 2027 revenue estimate is unchanged. Maintain BUY."

You May Also Be Interested In

• Wedbush Downgrades Tscan Therapeutics Inc (TCRX) to Neutral
• WBB Securities Starts Vogenx (VOGX) at Speculative Buy
• Comstock Resources (CRK) PT Raised to $17 at BMO Capital